Log in
Enquire now
Prospect Venture Partners

Prospect Venture Partners

A venture capital and private equity firm investing in biomedical technology companies.

OverviewStructured DataIssuesContributors

Contents

prospectventurepartners.com
prospectventures.com
Is a
Investor
Investor
Venture capital firm
Venture capital firm
Organization
Organization
Company
Company

Company attributes

Industry
Business development
Business development
Entrepreneurship
Entrepreneurship
Startup
Startup
Investment
Investment
Biotechnology
Biotechnology
Biology
Biology
...
Location
Palo Alto, California
Palo Alto, California
0
California
California
B2X
B2B
B2B
0
Founder
‌
Alex Barkas
AngelList URL
angel.co/prospect-v...re-partners
Pitchbook URL
pitchbook.com/profiles.../11277-46
Date Incorporated
1997
Phone Number
+16503278800
Full Address
525 University Avenue Suite 1350 Palo Alto, CA 94301 United States0
Founded Date
1997
Wellfound ID
prospect-venture-partners

Venture Capital Firm attributes

Invested in
NinePoint Medical
NinePoint Medical
Nora Therapeutics
Nora Therapeutics
NGM Biopharmaceuticals
NGM Biopharmaceuticals
Alvine Pharmaceuticals
Alvine Pharmaceuticals
Neomend
Neomend
Topica Pharmaceuticals
Topica Pharmaceuticals
Azelon Pharmaceuticals
Azelon Pharmaceuticals
Lux Biosciences
Lux Biosciences
...

Other attributes

Company Operating Status
Active

Prospect Venture Partners is a venture capital and private equity firm investing in biomedical technology companies that is headquartered in Palo Alto, California and was founded in 1997 by Alex Barkas.

Investments

According to the firms website (as of November 2019) they have raised over $1 billion in capital, led more than 50 funding rounds, and invest in seed and growth stage companies. Notable investments made by Prospect Venture Partners include: Amicus Therapeutics, Amira Pharmaceuticals, Cabochon, Complete Genomics, Gloucester Pharmaceuticals, Healtheon, Infinity Pharmaceuticals, Idun Pharmaceuticals, Intuitive Surgical, Kythera Biopharmaceuticals, SentreHeart, Rinat Neuroscience, Tinea Pharmaceuticals, Trubion, Visiogen, and Vitae Pharmaceuticals,

Investment funds
Fund III

On July 30, 2001 Prospect Venture Partners announced raising $500 million for their third venture capital fund. The fund will be used to invest in early-stage biotechnology, biopharmaceutical, and medical devices companies. Prospect Venture Partners will use the fund to make investments in approximately 30 companies ranging in size from $10 to $15 million.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Associated Investment Funds

Accelerator Batches

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Prospect Venture Partners

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.